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Only doubling or tripling a-synuclein expression significantly increases the risk of developing Parkinson’s
disease. In this issue of Neuron, Nemani et al. show that this modest overexpression of a-synuclein does
not lead to obvious toxicity in the near term, but impairs glutamate and dopamine release, potentially leading
to broad network dysfunction and eventual pathology.Parkinson’s disease (PD) is a widespread,
aging-related neurodegenerative disease.
One of the hallmarks of PD is the forma-
tion of intracellular proteinaceous inclu-
sions referred to as Lewy bodies (LBs)
(Braak et al., 2003). One of the principal
components of LBs is a-synuclein (asyn).
Elevating asyn expression by duplication
or triplication of the asyn gene (SNCA)
produces inclusions and increases the
risk of developing PD (Waxman and Gias-
son, 2009). The asyn protein also has
been implicated in a variety of other
neurodegenerative diseases, like Alz-
heimer’s disease and multiple system
atrophy, making it one of the most studied
molecules in the last decade.
Yet, in spite of all this effort, how modest
overexpression or mutation of asyn might
lead to neuronal pathology is still not
agreed upon. a-Synuclein is a small (140
amino acid), highly charged protein that is
preferentially localized in presynaptic
terminals (George et al., 1995) where it
has been suggested to shape synaptic
transmission (Abeliovich et al., 2000; Cabin
et al., 2002; Chandra et al., 2005; Fortin
et al., 2005). But, the putative synaptic
role of asyn is based largely upon the
consequences of knocking it out (where
the effects are modest at best) or upon
dramatically overexpressing it (where there
might be a toxic gain of function). In fact,
the effect of overexpressing asyn on
synaptic transmitter release has not been
directly examined. To be sure, the various
overexpressionmodelshave toldusa great
deal about the mechanisms underlying
synucleinopathies; however, what they tell
us about PD, where modest overexpres-
sion of asyn can significantly elevate the
risk of becoming symptomatic, is unclear.
The studies described in the article by
Nemani et al. in this issue ofNeuron (Nem-ani et al., 2010) bring us considerably
closer to an understanding of how this
might happen. Using an elegant combina-
tion of anatomical, optical, and physiolog-
ical approaches with both in vitro and
in vivo model systems, the authors show
that increasing the expression of asyn
by 2- to 3-fold inhibits neurotransmitter
release in glutamatergic hippocampal
pyramidal neurons and mesencephalic
dopaminergic neurons. At these expres-
sion levels, asyn has no obvious toxicity
and does not form intracellular inclusions
that foreshadow the formation of LBs.
The inhibition does not appear to be a
consequence of a reduction in the number
of transmitter-containing vesicles (as
judged from ultrastructural analysis) or of
a deficit in vesicular fusion or endocytosis
but rather of the failure to get recycling
vesicles clustered near synaptic release
sites. This clustering deficit reduces the
number of vesicles that fuse with the
membrane during an action potential
and, since quantal size is unchanged, to
a reduction in the amount of transmitter
released, particularly if the terminal is
pushed by repetitive stimulation. Because
asyn is widely expressed and the conse-
quences of its overexpression are not
limited to a particular cell type, Nemani
et al.’s results suggest that duplication
or triplication of SNCA should have
a negative impact on the functioning of
most, if not all, brain circuits.
Precisely how elevating asyn expres-
sion impairs clustering of vesicles near
the synapse remains to be worked out.
Not all the mutations of asyn associated
with familial forms of PD affected release
in the same way: asyn with the A30P
mutation lost its ability to inhibit trans-
mitter release, whereas asyn with the
A53T and E46K mutations retained thisNeuroncapacity, suggesting that amino terminal
membrane binding was a key step in the
inhibition. Synapsins and complexins—
proteins involved in vesicle mobilization
and fusion—were downregulated by
boosting the abundance of asyn. But the
authors argue that this alteration is not
enough to explain the observed syn-
aptic phenomenology, pointing to another
function of asyn. A potential clue about
this ‘‘other’’ role comes from the fact
that the effect on release is dose depen-
dent, scaling with the level of asyn
expression. This isn’t what would be ex-
pected ifasyn were taking on a completely
new role in synaptic function as expres-
sion rose. This dose dependence, along
with the ability of b- and g-synuclein to
substitute for asyn in regulating trans-
mitter release, suggests that asyn might
normally be more important in synaptic
function than one would infer from the
consequences of knocking it out.
What does this study tell us about path-
ogenesis in PD (or other synucleinopa-
thies)? One of the most widely discussed
features of the LB pathology in PD is its
distribution (Braak et al., 2003). Although
it is far from clear how LB formation is
linked to the severity of PD symptoms
(Jellinger, 2009), there is no doubt that
LBs are found distributed along the neu-
roaxis in early stages of the disease and
they are not limited to dopaminergic neu-
rons in the mesencephalon. The generic
deficit in transmitter release described
Nemani et al. is consistent with the prop-
osition that PD is a much broader disorder
than that inferred from the dopamine-
dependent motor symptoms. But how
a deficit in transmitter release might lead
to LB pathology or neurodegeneration is
unresolved at this point. It could be that
neurons attempt to compensate for the65, January 14, 2010 ª2010 Elsevier Inc. 3
Neuron
Previewsinhibition by increasing spiking or by
elevating other aspects of synaptic trans-
mission (although neither was seen in the
time frame of the experiments conducted
here). A compensation of this sort could
impair global brain function and modestly
elevate the proteostatic burden on neu-
rons, resulting in a slow accumulation of
cellular deficits that results in relatively
widespread LB formation only late in life.
Although the deficit predicted by Nem-
ani et al. should be widespread, it is
possible that its impact is felt more by
some neurons than others. Some of the
most vulnerable neurons in PD—dopami-
nergic neurons in the substantia nigras
pars compacta, noradrenergic neurons
in the locus ceruleus, serotonergic neu-
rons in the raphe nuclei, and cholinergic
neurons in the basal forebrain nuclei
(Jellinger, 1991)—have enormous axonal
fields with orders of magnitude more
synaptic terminals than most neurons
(e.g., Matsuda et al., 2009). Moreover, all
of these neurons are spontaneously
active in vivo, continually releasing trans-
mitter in target structures like the striatum,
cerebral cortex, and hippocampus (Bara-
ban and Aghajanian, 1980; Chan et al.,
2007; Vinogradova et al., 1980; Williams4 Neuron 65, January 14, 2010 ª2010 Elsevieet al., 1984). This sustained transmitter
release is important to their targets, and
all of these neurons have feedback sys-
tems at their terminals (e.g., autorecep-
tors that regulate the entry of calcium trig-
gering exocytosis) to make sure that they
are doing their job. It is not difficult to
imagine that compromising the ability of
these neurons to release transmitter
might force them to work even harder
than demanded by their normal role in
brain, and that, after fifty or sixty years,
they are left with axonal pathology (Galvin
et al., 1999) and LBs.REFERENCES
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The mechanisms underlying the brain response to systemic inflammation remain unclear. In this issue of
Neuron, Serrats and colleagues demonstrate that two cell types that produce prostaglandins that act on
the brain, perivascular and endothelial cells, have an unexpectedly complex interaction in regulating the
timing and types of brain responses that occur.During systemic inflammation, there is
a stereotyped set of responses that are
mediated by the brain. These includeelevation of body temperature (fever),
anorexia, reduction of pain thresholds,
disruption of sleep cycles, and elevationof corticosteroids (Elmquist et al., 1997b).
The very fact that these responses are
so stereotyped across many types of
